O	0	11	Feasibility
O	12	14	of
O	15	18	two
B-intervention	19	23	dose
I-intervention	23	24	-
I-intervention	24	29	dense
I-intervention	30	33	FEC
I-intervention	34	42	regimens
O	43	47	with
O	48	54	growth
O	55	61	factor
O	62	69	support
O	70	73	for
O	74	82	adjuvant
O	83	90	therapy
O	91	93	in
B-eligibility	94	102	patients
I-eligibility	103	107	with
I-eligibility	108	113	early
I-eligibility	114	120	breast
I-eligibility	121	127	cancer
O	127	128	:
O	129	136	results
O	137	141	from
O	142	143	a
O	144	154	randomised
O	155	160	study
O	161	163	of
O	164	167	the
O	168	175	Central
O	176	184	European
O	185	196	Cooperative
O	197	205	Oncology
O	206	211	Group
O	212	213	(
O	213	218	CECOG
O	218	219	)
O	219	220	.

O	221	229	Addition
O	230	232	of
O	233	243	epirubicin
O	244	246	to
O	247	255	adjuvant
O	256	268	chemotherapy
O	269	272	can
O	273	280	provide
O	281	290	important
O	291	299	benefits
O	300	303	for
O	304	312	patients
O	313	317	with
O	318	323	early
O	324	330	breast
O	331	337	cancer
O	337	338	,
O	339	342	but
O	343	346	the
O	347	354	optimal
O	355	359	dose
O	360	367	remains
O	368	375	unclear
O	375	376	.

O	377	384	Further
O	385	397	improvements
O	398	401	can
O	402	404	be
O	405	413	achieved
O	414	418	with
O	419	423	dose
O	423	424	-
O	424	429	dense
O	430	438	regimens
O	438	439	,
O	440	443	but
O	444	457	densification
O	458	460	of
O	461	473	fluorouracil
O	473	474	/
O	474	484	epirubicin
O	484	485	/
O	485	501	cyclophosphamide
O	502	503	(
O	503	506	FEC
O	506	507	)
O	508	511	has
O	512	518	proved
O	519	528	difficult
O	528	529	,
O	530	534	with
O	535	538	FEC
O	538	539	(
O	539	541	60
O	541	542	)
O	543	552	providing
O	553	559	little
O	560	567	benefit
O	568	572	over
O	573	581	standard
O	582	594	chemotherapy
O	595	598	and
O	599	602	FEC
O	602	603	(
O	603	606	100
O	606	607	)
O	608	618	associated
O	619	623	with
O	624	632	toxicity
O	632	633	.

O	634	636	We
O	637	649	investigated
O	650	653	the
O	654	665	feasibility
O	666	668	of
O	669	672	two
O	673	685	intermediate
O	686	690	dose
O	690	691	-
O	691	696	dense
O	697	700	FEC
O	701	709	regimens
O	709	710	.

O	711	719	Patients
O	720	724	were
O	725	735	randomised
O	736	738	to
O	739	742	six
O	743	749	cycles
O	750	752	of
O	753	756	FEC
O	756	757	(
O	757	759	75
O	759	760	)
O	761	763	or
B-control	764	767	FEC
I-control	767	768	(
I-control	768	770	90
I-control	770	771	)
O	771	772	,
O	773	777	with
O	778	781	all
O	782	787	three
O	788	793	drugs
O	794	799	given
O	800	802	on
O	803	806	day
O	807	808	1
O	809	811	of
O	812	816	each
O	817	819	14
O	819	820	-
O	820	823	day
O	824	829	cycle
O	829	830	.

O	831	839	Patients
O	840	844	also
O	845	853	received
O	854	867	pegfilgrastim
O	868	869	6
O	870	872	mg
O	873	875	as
O	876	877	a
O	878	884	single
O	885	897	subcutaneous
O	898	907	injection
O	908	910	on
O	911	914	day
O	915	916	2
O	917	919	of
O	920	924	each
O	925	930	cycle
O	930	931	.

O	932	935	The
O	936	943	primary
O	944	952	efficacy
O	953	961	endpoint
O	962	965	was
O	966	969	the
B-outcome	970	980	proportion
I-outcome	981	983	of
I-outcome	984	992	subjects
I-outcome	993	1002	receiving
I-outcome	1003	1004	>
I-outcome	1005	1007	or
I-outcome	1008	1009	=
I-outcome	1009	1011	85
I-outcome	1011	1012	%
I-outcome	1013	1021	relative
I-outcome	1022	1026	dose
I-outcome	1027	1036	intensity
O	1037	1040	and
O	1041	1044	was
O	1045	1053	achieved
O	1054	1056	by
B-iv-bin-percent	1057	1059	96
I-iv-bin-percent	1059	1060	%
O	1061	1064	and
B-cv-bin-abs	1065	1067	88
I-cv-bin-abs	1067	1068	%
O	1069	1071	of
O	1072	1080	patients
O	1081	1083	in
O	1084	1087	the
O	1088	1091	FEC
O	1091	1092	(
O	1092	1094	75
O	1094	1095	)
O	1096	1099	and
O	1100	1103	FEC
O	1103	1104	(
O	1104	1106	90
O	1106	1107	)
O	1108	1112	arms
O	1112	1113	,
O	1114	1126	respectively
O	1126	1127	.

O	1128	1130	Of
B-intervention-participants	1131	1134	147
O	1135	1138	FEC
O	1138	1139	(
O	1139	1141	75
O	1141	1142	)
O	1143	1152	infusions
O	1152	1153	,
B-iv-bin-percent	1154	1155	4
I-iv-bin-percent	1155	1156	.
I-iv-bin-percent	1156	1157	1
I-iv-bin-percent	1157	1158	%
O	1159	1163	were
O	1164	1171	delayed
O	1171	1172	,
O	1173	1178	while
B-cv-bin-percent	1179	1180	9
I-cv-bin-percent	1180	1181	.
I-cv-bin-percent	1181	1182	8
I-cv-bin-percent	1182	1183	%
O	1184	1186	of
B-control-participants	1187	1190	143
O	1191	1194	FEC
O	1194	1195	(
O	1195	1197	90
O	1197	1198	)
B-outcome	1199	1208	infusions
I-outcome	1209	1213	were
I-outcome	1214	1221	delayed
O	1221	1222	.

O	1223	1226	The
O	1227	1231	most
O	1232	1238	common
O	1239	1246	reasons
O	1247	1250	for
O	1251	1256	delay
O	1257	1261	were
O	1262	1269	adverse
O	1270	1276	events
O	1277	1280	and
O	1281	1289	personal
O	1289	1290	/
O	1290	1300	logistical
O	1301	1308	reasons
O	1308	1309	.

B-cv-bin-abs	1310	1313	One
O	1314	1318	dose
O	1319	1328	reduction
O	1329	1337	occurred
O	1338	1344	during
O	1345	1348	the
O	1349	1354	study
O	1355	1356	(
O	1356	1359	FEC
O	1359	1360	(
O	1360	1362	90
O	1362	1363	)
O	1363	1364	)
O	1364	1365	,
O	1366	1373	related
O	1374	1376	to
B-outcome	1377	1386	diarrhoea
O	1386	1387	.

B-outcome	1388	1393	Grade
I-outcome	1394	1395	3
I-outcome	1395	1396	-
I-outcome	1396	1397	4
I-outcome	1398	1412	haematological
I-outcome	1413	1423	toxicities
O	1424	1428	were
O	1429	1437	reported
O	1438	1440	in
B-cv-bin-abs	1441	1444	two
O	1445	1453	patients
O	1454	1456	in
O	1457	1460	the
O	1461	1464	FEC
O	1464	1465	(
O	1465	1467	90
O	1467	1468	)
O	1469	1472	arm
O	1472	1473	.

O	1474	1479	There
O	1480	1484	were
O	1485	1487	no
B-outcome	1488	1498	incidences
I-outcome	1499	1501	of
I-outcome	1502	1509	febrile
I-outcome	1510	1521	neutropenia
O	1522	1528	during
O	1529	1532	the
O	1533	1538	study
O	1538	1539	.

O	1540	1543	The
O	1544	1548	most
O	1549	1555	common
O	1556	1563	adverse
O	1564	1570	events
O	1571	1575	were
B-outcome	1576	1585	increases
I-outcome	1586	1588	in
I-outcome	1589	1594	liver
I-outcome	1595	1602	enzymes
I-outcome	1603	1606	and
I-outcome	1607	1623	gastrointestinal
I-outcome	1624	1630	events
O	1630	1631	;
O	1632	1634	no
O	1635	1640	event
O	1641	1649	resulted
O	1650	1652	in
O	1653	1668	discontinuation
O	1668	1669	.

O	1670	1674	Only
B-cv-bin-abs	1675	1678	one
O	1679	1686	patient
O	1687	1688	(
O	1688	1691	FEC
O	1691	1692	(
O	1692	1694	90
O	1694	1695	)
O	1695	1696	)
O	1697	1708	experienced
B-outcome	1709	1716	serious
I-outcome	1717	1724	adverse
I-outcome	1725	1731	events
I-outcome	1732	1733	(
I-outcome	1733	1741	vomiting
I-outcome	1742	1745	and
I-outcome	1746	1752	throat
I-outcome	1753	1759	oedema
I-outcome	1759	1760	)
O	1760	1761	.

O	1762	1764	In
O	1765	1775	conclusion
O	1775	1776	,
O	1777	1781	dose
O	1781	1782	-
O	1782	1787	dense
O	1788	1791	FEC
O	1791	1792	(
O	1792	1794	75
O	1795	1796	)
O	1796	1799	and
O	1800	1803	FEC
O	1803	1804	(
O	1804	1806	90
O	1806	1807	)
O	1808	1811	are
O	1812	1820	feasible
O	1821	1825	with
O	1826	1839	pegfilgrastim
O	1840	1847	support
O	1847	1848	.

O	1849	1854	These
O	1855	1863	regimens
O	1864	1867	are
O	1868	1878	associated
O	1879	1883	with
O	1884	1885	a
O	1886	1890	very
O	1891	1894	low
O	1895	1899	risk
O	1900	1902	of
O	1903	1908	Grade
O	1909	1910	3
O	1910	1911	-
O	1911	1912	4
O	1913	1921	toxicity
O	1921	1922	.
